Cardiometabolic Risk, Part 1: Chemotherapy and Radiotherapy - Old Foes Still Threatening Cancer Survivors?

Maja Vestmø Maraldo, Alessandro Andreis, Ilenia Iamundo de Cumis, Marzia Cerrato, Angelisa Vella, Umberto Ricardi, Mario Levis

Abstract

Long-term cancer survivors are at high risk of developing cardiac complications from the treatments, both systemic agents and thoracic irradiation, received to cure the primary tumor. Modern advances, particularly in the field of radiotherapy, aim to reduce the risk of cardiovascular disease. Also, new diagnostic tools increasingly improve their efficacy in early detection of the preclinical treatment-induced cardiac damage. In this review, we summarize the mechanisms of radiotherapy- and chemotherapy-induced cardiac injury, the available clinical data, the strategies to mitigate cardiac exposure with modern radiotherapy and the current diagnostic tools for an early detection and prompt management of these complications in long-term cancer survivors.

Original languageEnglish
Title of host publicationCardiometabolic Risk, Part 1: Chemotherapy and Radiotherapy - Old Foes Still Threatening Cancer Survivors?
Number of pages15
Volume54
Publication date2021
Pages115-129
DOIs
Publication statusPublished - 2021
SeriesFrontiers of Hormone Research
ISSN0301-3073

Fingerprint

Dive into the research topics of 'Cardiometabolic Risk, Part 1: Chemotherapy and Radiotherapy - Old Foes Still Threatening Cancer Survivors?'. Together they form a unique fingerprint.

Cite this